Reported 8 months ago
Despite optimistic long-term prospects for curative gene therapy and CRISPR Therapeutics (NASDAQ:CRSP) stock, a realistic view is needed due to the development of treatment centers and the necessity for more long-term data. Although it may take some time for CRISPR stock to soar, the company's leading position in gene-editing technology remains promising. CRISPR Therapeutics has introduced life-changing treatments for genetic diseases, with its first product CASGEVY targeting sickle cell disease (SCD) and beta-thalassemia, impacting over 300,000 newborns yearly. The therapy costs approximately $2.2 million per patient and has received approvals in key markets, signaling potential growth in treating genetic diseases. However, challenges such as establishment of treatment centers and slow adoption rates may hinder immediate stock surges. Nevertheless, analysts view CRISPR Therapeutics as a promising investment with a Moderate Buy rating and 30.6% upside potential according to TipRanks.
Source: YAHOO